Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Proposed financing at InSite to advance AzaSite development

June 4, 2004

Allergan and Kyorin sign Japanese agreement for Alphagan franchise

June 2, 2004

FDA sets date to discuss Macugen NDA

June 1, 2004

Allergan presents new prostaglandin analogues with utility as ocular hypotensive agents

May 28, 2004

NDA filing for Xibrom

May 27, 2004

Allergan and Senju sign Japanese licensing agreement for Lumigan

May 27, 2004

Novel ocular hypotensive agent BVT-28949 effective in monkeys

May 20, 2004

Pharmacokinetics and efficacy of ranibizumab in exudative AMD

May 14, 2004

Prostanoid compound RUG-015 effectively reduces intraocular pressure

May 14, 2004

Novel somatostatin conjugate effective for treatment of choroidal neovascularization in vivo

May 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...